1991
DOI: 10.1016/0142-9612(91)90207-q
|View full text |Cite
|
Sign up to set email alerts
|

In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
78
1
3

Year Published

1993
1993
2014
2014

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 209 publications
(82 citation statements)
references
References 31 publications
0
78
1
3
Order By: Relevance
“…To maintain the scaffold structure and shape after seeding the cells and during implantation, the scaffolds should be mechanically strong, because the dermis needs to provide physical support and flexibility to the skin. Biodegradable synthetic polymers such as poly(l-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(dl-lactic-co-glycolic acid) (PLGA) and poly (ε-caprolactone) (PCL) have also been used to prepare porous scaffolds for skin tissue engineering [6,7]. The scaffolds prepared from biodegradable synthetic polymers have favorable mechanical properties.…”
Section: Introductionmentioning
confidence: 99%
“…To maintain the scaffold structure and shape after seeding the cells and during implantation, the scaffolds should be mechanically strong, because the dermis needs to provide physical support and flexibility to the skin. Biodegradable synthetic polymers such as poly(l-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(dl-lactic-co-glycolic acid) (PLGA) and poly (ε-caprolactone) (PCL) have also been used to prepare porous scaffolds for skin tissue engineering [6,7]. The scaffolds prepared from biodegradable synthetic polymers have favorable mechanical properties.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical studies have shown it to be useful as a dermal substitute in full thickness burns without signs of rejection, showing revascularisation, cellular repopulation, incorporation into the wound and cosmetic results similar to intermediate thickness skin grafts (Wainwright et al 1996). Dermagraft (Cooper et al 1991) is fabricated by seeding and maintaining fibroblasts on a Vicryl mesh for a period of 2 to 3 weeks to achieve a sufficient amount of tissue formation for a therapeutic effect. The product is currently FDA approved for the treatment of venous (Omar et al 2004), neuropathic and diabetic ulcers (Marston et al 2003).…”
Section: Collagen Dermal Tissue Equivalentsmentioning
confidence: 99%
“…The fibroblasts become confluent within the polymer mesh, secreting growth factors and dermal matrix proteins (collagens, tenascin, vitronectin, and glycosaminoglycans), thus creating a living dermal structure [35]. This remains viable and metabolically active after implantation into the wound, despite cryopreservation [36]. Dermagraft facilitates healing by stimulating the ingrowth of fibrovascular tissue from the wound bed and re-epithelialization from the wound edges.…”
Section: Dermagraftmentioning
confidence: 99%